Skip to main content
AACR Project GENIE v19.0 · 21,017 myeloid samples Panel-adjusted Fisher's exact with Benjamini-Hochberg FDR N=1 case study · Not clinical guidance

Clinical Trials and Drug Repurposing

ClinicalTrials.gov matches, VICC Meta-Knowledgebase federated evidence, OncoKB actionability, and treatment strategy for five driver mutations.

Clinical Trials
33
18 recruiting at the 2 Nov 2026 recheck; 8 trials have a European site
Recruiting Active
18
ClinicalTrials.gov API v2 status on 2 Nov 2026 (21 at the March 2026 query)
VICC Evidence
263
From 5 databases with hits (CIViC, CGI, JAX, OncoKB, PMKB); MolecularMatch returned none
OncoKB Level 1 FDA
IDH2 R140Q
Enasidenib: FDA-approved 2017 for R/R AML with IDH2 mutation

Treatment Strategy

Backbone: Venetoclax + azacitidine with enasidenib for the IDH2 R140Q subclone (VAF 2%). The patient is currently MRD-negative and in full donor chimerism 35 months post-allogeneic HSCT. Treatment considerations are for relapse contingency planning.

Actionable targets: (1) IDH2 R140Q: enasidenib (FDA-approved 2017, OncoKB Level 1). ORR 40.3%, CR 19.3% in R/R AML 21
[21] EM 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017)
. NCT03728335 (enasidenib maintenance post-HSCT) matched the post-transplant setting, but has been suspended since August 2026 (accrual goal met). (2) PTPN11 E76Q: SHP2 inhibitors are investigational only. TNO155 23
[23] MJ 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020)
has Phase I and I/II trials in solid tumours only, none in leukemia or MDS; RMC-4550 has no registered trial (ClinicalTrials.gov, 2 Nov 2026). The earlier AutoDock Vina scores were computed on ligand structures that turned out to be the wrong molecules and are superseded; the docking with PubChem-verified structures (Boltz-2 and DiffDock 2.0, 15 Apr 2026) is on the Molecular Docking page.

CONTRAINDICATION: Tazemetostat (EZH2 inhibitor) is CONTRAINDICATED. EZH2 V662A is loss-of-function, not gain-of-function. Tazemetostat inhibits EZH2 catalytic activity, which is already impaired by V662A. Administering tazemetostat would further reduce H3K27me3; EZH2 loss-of-function mutations in myeloid neoplasms are associated with adverse prognosis 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
. On March 9, 2026 Ipsen voluntarily withdrew tazemetostat in all indications and markets after hematologic second cancers (mostly MDS and AML) emerged in the SYMPHONY-1 trial, consistent with the LoF concern in myeloid settings.
IDH2 R140Q FDA
Level 1
Enasidenib (AG-221), approved 2017
PTPN11 E76Q
No myeloid trial
TNO155: solid-tumour trials only; RMC-4550: no registered trial
EZH2 V662A Blocked
CONTRA
Tazemetostat: LoF variant, inhibitor CONTRAINDICATED
DNMT3A R882H
HMA
Azacitidine/decitabine (indirect, backbone therapy)
SETBP1 G870S
No Target
PP2A activators (FTY720, DT-061) preclinical only

Drug Landscape

The drug landscape spans FDA-approved agents (enasidenib, venetoclax, azacitidine), investigational SHP2 inhibitors (Phase I/II in solid tumours only), and preclinical repurposing candidates (PP2A activators for SETBP1). Of the 5 driver mutations, 1 is directly druggable with an approved drug (IDH2 R140Q), 1 has investigational inhibitors with no myeloid trial (PTPN11 E76Q), 1 has an indirect HMA-based approach (DNMT3A R882H), 1 has only preclinical candidates (SETBP1 G870S), and 1 requires avoidance of the standard inhibitor class (EZH2 V662A).
TargetDrugMechanismStatusLevel
IDH2 R140QEnasidenib (AG-221 / Idhifa)Selective IDH2 inhibitor — blocks 2-HG production by mutant IDH2, restores norma...FDA ApprovedApproved
IDH2 R140QVorasidenib (AG-881)Dual IDH1/IDH2 inhibitor — brain-penetrant, primarily studied in gliomaFDA-approved for glioma only, not AMLPhase 1 (for AML context — off-label consideration)
PTPN11 (SHP2) E76QRMC-4550 (Revolution Medicines)Allosteric SHP2 inhibitor — locks SHP2 in autoinhibited conformation, blocks RAS...No registered trialsPhase 1/2
PTPN11 (SHP2) E76QTNO155 (Novartis)Allosteric SHP2 inhibitorPhase 1/2Phase 1/2
PTPN11 (SHP2) E76QJAB-3312 (Jacobio Pharmaceuticals)Allosteric SHP2 inhibitorPhase 1/2Phase 1/2
PTPN11 (SHP2) E76QRMC-4630 (Revolution Medicines)Allosteric SHP2 inhibitor — clinical-grade compound from same programme as RMC-4...Phase 1/2Phase 1/2
DNMT3A R882HAzacitidine (Vidaza)Hypomethylating agent (HMA) — DNA methyltransferase inhibitor, induces hypomethy...FDA ApprovedApproved
DNMT3A R882HDecitabine (Dacogen)Hypomethylating agent — similar mechanism to azacitidine but pure deoxynucleosid...FDA ApprovedApproved
DNMT3A R882HDecitabine/Cedazuridine (Inqovi)Oral HMA — decitabine + CDA inhibitor for oral bioavailabilityFDA ApprovedApproved
SETBP1 G870SFTY720 (Fingolimod) — PP2A activatorPP2A activating drug (PAD) — disrupts SET-PP2A interaction, reactivates PP2A tum...FDA ApprovedPreclinical (for AML)
SETBP1 G870SOP449 (formerly SET antagonist peptide)Cell-penetrating peptide that binds SET and releases PP2A from SET-mediated inhi...PreclinicalPreclinical
SETBP1 G870SDT-061 (SMAP class)Small molecule activator of PP2A — stabilises active B56alpha-containing PP2A ho...PreclinicalPreclinical
General AML N/AVenetoclax (Venclexta)BCL-2 inhibitor — induces apoptosis in AML cells dependent on BCL-2 for survivalFDA ApprovedApproved
General AML N/AMidostaurin (Rydapt)Multi-kinase inhibitor (FLT3, KIT, PDGFR, VEGFR, PKC)FDA ApprovedNot applicable unless FLT3-mutated
General AML N/AGilteritinib (Xospata)FLT3 inhibitor (FLT3-ITD and FLT3-TKD)FDA ApprovedNot applicable unless FLT3-mutated
Monosomy 7 -7EZH2 inhibitors (tazemetostat) — synthetic lethality conceptIf monosomy 7 removes one EZH2 allele, remaining allele may be haploinsufficient...Contraindicated here (EZH2 V662A LoF)Preclinical
Monosomy 7 -7Allogeneic stem cell transplantOnly curative option for monosomy 7 — replaces malignant clone with donor haemat...Standard of careApproved (transplant)
Table 1.Drug-target landscape for patient mutation profile. Excludes tool compounds and non-applicable agents.
Source: Compiled from DrugBank, OncoKB, DGIdb, ClinicalTrials.gov, and published literature.

VICC Meta-Knowledgebase

Total Hits
263
Across 5 databases with hits
DNMT3A R882H
55
55 associations across CIViC, JAX, PMKB, CGI, OncoKB
IDH2 R140Q
73
73 associations, 19 variant-specific, incl. Level A enasidenib
EZH2 V662A
105
105 associations (mostly gene-level, not variant-specific)
The VICC Meta-Knowledgebase 47
[47] AH 2020
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet (2020)
federates clinical evidence across CIViC 36
[36] M 2017
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet (2017)
, CGI, JAX-CKB, OncoKB 35
[35] D 2017
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017)
and PMKB; MolecularMatch was also queried but returned no hits. Querying all 5 patient variants yields 263 total associations spanning predictive, diagnostic, prognostic, and therapeutic evidence. EZH2 V662A has the most hits (105), but all are gene-level (70) or co-occurrence (35) annotations with no variant-specific hit, so none describes V662A itself. IDH2 R140Q (73 hits) carries Level A (FDA-approved) enasidenib data; DNMT3A R882H has the most variant-specific hits (29). SETBP1 G870S has the sparsest evidence (6 hits), reflecting the limited therapeutic landscape for this target.
GeneVariantTotal HitsTop SourceEvidence Levels
DNMT3AR882H55CIVIC (41)B:40, A:6, D:5, C:3
IDH2R140Q73jax (35)A:26, B:21, C:13, D:12
SETBP1G870S6jax (3)D:2, C:2, A:1, B:1
PTPN11E76Q24jax (20)D:17, B:5, A:1, C:1
EZH2V662A105jax (76)D:76, A:13, C:9, B:7
Table 2.Per-variant evidence summary from the VICC federated knowledgebase.
Source: VICC Meta-Knowledgebase (Wagner et al., Nat Genet, 2020). Evidence levels: A (FDA/guidelines), B (clinical evidence), C (case reports), D (preclinical).

OncoKB Clinical Actionability

OncoKB 35
[35] D 2017
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017)
classifies IDH2 R140Q as Level 1 (FDA-approved targeted therapy), the highest actionability designation. Of the other 4 variants, OncoKB (AML, API query 3 Nov 2026, data v7.7) classifies DNMT3A R882H and SETBP1 G870S as Oncogenic, PTPN11 E76Q as Likely Neutral and EZH2 V662A as Unknown; none of the 4 has an OncoKB therapeutic level. OncoKB therefore supports 3 of the 5 variants as oncogenic; the 5-driver classification rests on the ACMG evidence on the Pathogenicity page.
GeneVariantOncogenicityEffectHighest LevelDrug
EZH2V662AUnknownUnknownNoneNo targeted therapy
DNMT3AR882HOncogenicLoss-of-functionNoneNo targeted therapy
SETBP1G870SOncogenicGain-of-functionNoneNo targeted therapy
PTPN11E76QLikely NeutralLikely NeutralNoneNo targeted therapy
IDH2R140QOncogenicSwitch-of-functionLevel 1Enasidenib
Table 3.OncoKB clinical actionability annotations for all 5 patient variants.
Source: OncoKB (Chakravarty et al., JCO PO, 2017). Tumor type context: Acute Myeloid Leukemia. Level 1: FDA-approved. The other 4 variants have no OncoKB level.

Matched Clinical Trials

33 clinical trials matched the patient's mutation profile via the ClinicalTrials.gov API v2 (query of 27 Mar 2026). At the status recheck on 2 Nov 2026, 18 are recruiting (21 in March). Trials are scored by eligibility criteria overlap with the patient's specific mutations, diagnosis (MDS-AML), age (36), and post-HSCT status. The highest-scored trial is NCT03383575 (azacitidine + enasidenib for IDH2-mutant MDS, score 100). The most directly relevant for current status was NCT03728335 (enasidenib maintenance post-allogeneic HCT in IDH2-mutant patients, score 88), now suspended (accrual goal met, August 2026).
NCT IDTitlePhaseStatusTargetScore
NCT03383575Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic...Ph 2RecruitingIDH2 R140Q100
NCT06387069A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid ...Ph 3RecruitingIDH2 R140Q99
NCT04603001Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With ...Ph 1ActiveIDH2 R140Q96
NCT02632708Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation...Ph 1ActiveIDH2 R140Q92
NCT03825796CPX-351 Plus Enasidenib for Relapsed AMLPh 2ActiveIDH2 R140Q91
NCT04774393Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enaside...Ph 1, PHASE2RecruitingIDH2 R140Q91
NCT03728335Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutati...Ph 2SUSPENDEDIDH2 R140Q88
NCT05010772Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or...Ph 1RecruitingIDH2 R140Q + combination therapy88
NCT06577441Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedaz...Ph 2RecruitingIDH2 R140Q85
NCT05441514Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refr...Ph 1COMPLETEDIDH2 R140Q85
NCT06377579OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute...Not specifiedRecruitingIDH2 R140Q84
NCT06611839Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed ID...Ph 1, PHASE2RecruitingIDH2 R140Q83
Table 4.Top 12 matched clinical trials ranked by eligibility score. Status as of 2 Nov 2026. NCT IDs link to ClinicalTrials.gov.
Source: ClinicalTrials.gov API v2. Queried: IDH2 AML, SHP2 myeloid, venetoclax + azacitidine + IDH2, PTPN11 leukemia, MDS monosomy 7, enasidenib combinations. Eligibility scores incorporate mutation match, diagnosis, age, and HSCT status.
References
  1. Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017). DOI
  2. Chase A, Score J, Lin F, et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). DOI
  3. LaMarche MJ et al. Identification of TNO155, an allosteric SHP2 inhibitor for cancer therapy. J Med Chem (2020). DOI
  4. Chakravarty D et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017). DOI
  5. Wagner AH et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet (2020). DOI
  6. Griffith M et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet (2017). DOI
  7. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function. J Comput Chem (2010). DOI